We are live on ! Find out more
AIM

Alerce Investment Management Portfolio holdings

AUM $56.8M
1-Year Est. Return 31.17%
This Fund
S&P 500
This Quarter Est. Return
-16.2%
1 Year Est. Return
+31.17%
3 Year Est. Return
+25.12%
5 Year Est. Return
10 Year Est. Return
AUM
$184M
AUM Growth
-$41.8M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
7
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMWL icon
1
American Well
AMWL
$180M
$79.3M 43.02%
315,039
ANNX icon
2
Annexon
ANNX
$834M
$44M 23.89%
1,954,978
RNTX
3
Rein Therapeutics
RNTX
$63.1M
$20.8M 11.27%
830,472
AKBA icon
4
Akebia Therapeutics
AKBA
$354M
$17.6M 9.57%
4,652,561
WHWK
5
Whitehawk Therapeutics
WHWK
$190M
$9.5M 5.16%
374,789
ASMB icon
6
Assembly Biosciences
ASMB
$498M
$8.64M 4.69%
185,625
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.42M 2.4%
126,270

Similar funds

Alerce Investment Management's Q2 2021 Portfolio in Review

As of Q2 2021, Alerce Investment Management held 7 positions worth $184M, down 18% from $226M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2021: portfolio turnover was 0%. Alerce Investment Management opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Alerce Investment Management's ten largest holdings make up 100% of its $184M portfolio in Q2 2021.
  • Alerce Investment Management opened 0 new positions and closed 0 in Q2 2021.
  • Alerce Investment Management's portfolio value fell 18% quarter-over-quarter to $184M.

Based on Alerce Investment Management's 13F filing for Q2 2021, filed 11 Aug 2021.